RenovoRx Announces First Patient Enrolled At University Of Nebraska Medical Center For Pivotal Phase III TIGeR-PaC Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
RenovoRx has announced the enrollment of the first patient at the University of Nebraska Medical Center for its pivotal Phase III TIGeR-PaC clinical trial.
August 14, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx has enrolled the first patient in its Phase III TIGeR-PaC clinical trial at the University of Nebraska Medical Center, marking a significant milestone in the development of its treatment.
The enrollment of the first patient in a pivotal Phase III clinical trial is a critical milestone for RenovoRx, indicating progress in the development of its treatment. This news is likely to positively impact the stock price in the short term as it demonstrates advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100